Evidence highlight
Science you can feel. Every active below is clinically studied and carefully dosed for real‑world results.
The 20Â mg daily dosage of Q-Actin studied in this clinical trial demonstrated significant and meaningful benefits for joint health compared to the placebo.
20Â mg daily improved joint comfort with meaningful pain reduction by 6Â months and significantly enhanced daily mobility.
Primary Finding
Significant reduction in knee discomfort scoresover a 6-month period.
Mobility Improvement
Enhanced functional ability, including walking,standing, and climbing stairs.
Safety Profile
Q-Actin was found to be safe and well-toleratedby all participants
Primary and Secondary Outcomes
The findings demonstrate a statistically significant difference between the Q-Actin group and the placebo group, confirming the extract's efficacy.
Primary Outcome: Reduction in Joint Discomfort
The 20Â mg daily dose of Q-Actin resulted in a substantial and progressive reduction in overall discomfort, as measured by the WOMAC Pain sub-score.
- At 3Â Months:
Participants taking Q-Actin reported significantly less pain compared to the placebo group. - At 6Â Months:
he Q-Actin group achieved a maximum average reduction of 48% in their WOMAC Pain score from the baseline. [Add Graph: Line chart comparing % reduction in WOMAC Pain score over 6 months for Q-Actin vs. Placebo.]
Secondary Outcome: Functional Mobility Improvement
Q-Actin not only reduced discomfort but also improved the ability of participants to perform daily activities.
- WOMAC Stiffness & Function Scores:
Significant improvement was seen in scores related to joint stiffness and physical function (including walking on a flat surface, standing, andusing stairs). - Quality of Life:
The enhanced mobility led to a measurable improvement in the overall quality of life for the Q-Actin group.
Coming Soon
50% OFF
50% OFF
